



**Doncaster Place & Bassetlaw Place Medicines Optimisation
Committee (PMOC)
Sections 1&2 (Area Prescribing and Formulary)
Thursday 17th July 2025
Via MS Teams
Minutes**

Committee Members:	✓ x	Area Prescribing	Formulary
Rao Kolusu (Chair) Doncaster Place	RK	✓	✓
Ewa Gabzdyl (Deputy Chair)(1 rep from Doncaster Place)	EG	✓	✓
Erica Carmody (only when EG cannot attend)	EC	x	x
Rob Wise Bassetlaw Place	RW	✓	✓
Lee Wilson DBTHFT (1 rep from DBTHFT)	LW	✓	✓
Rachel Wilson DBTHFT (when LW cannot attend)	RaW	x	x
Steve Davies RDaSH FT (1 rep from RDaSH FT)	SD	x	x
Andrew Houston RDaSH FT	AHo	x	x
Rachel Hubbard Doncaster Place	RH	✓	✓
Mallicka Chakrabarty Bassetlaw (Area Prescribing only)	MC	✓	✓
Dean Eggitt LMC	DE	✓	x
Rumit Shah LMC (when DE cannot attend)	RS	x	x
Prakash Navaneetharjah (PCD Doncaster North)	PN	✓	✓
Sonia Griffiths (PCD Doncaster 4D) On Mat Leave until June 25	SG	✓	✓
Lisa Sharp Doncaster NMP	LS	x	x
Pankaj Chatuvedi DBTHFT (Formulary only)	PC	✓	x
Charlotte McMurray (SY ICB MO Team) (Only when needed)	CMcM	x	x
Ashley Hill Doncaster MOT (only when needed)	AH	✓	✓
Jen Cox Doncaster MOT (Only when needed)	JC	x	x
Karen Jennison Doncaster MOT	KJ	x	x
In attendance:			
Kamran Raoof		✓	✓

✓ x – Indication of attendance to each section of the meeting (where required to attend)

SY ICB – South Yorkshire Integrated Care Board

IMOC – Integrated Medicines Optimisation Committee

PMOC – Place Medicines Optimisation Committee

MOT – Medicines Optimisation Team

TLS – Traffic Light System

MPD- Medicines and Product Directory

SCP – Shared Care Protocol



Agenda Ref	Subject / Action Required	Action Required By										
	Welcome, Introductions and Housekeeping: - Fire Alarm Procedure: N/A											
	Apologies for Absence: Apologies received from Karen Jennison; Ashley Hill was in attendance as minute secretary. Apologies received from Steve Davies In attendance: Kamran Raoof The meeting was noted at Quorate.											
	Declarations of Interest ICB Register of Interests											
	Notification of Any Other Business Pre-emptive prescribing review											
	Minutes and actions of the last Meeting The minutes of the meeting held in June 2025 were approved as a true record Action: Karen Jennison will distribute the ratified minutes to the appropriate list. Action log The action log was discussed and updated accordingly. MO Bulletin The June 2025 MO Bulletin was noted.	KJ										
07/25/1.1	Matters arising not on the agenda											
	N/A											
07/25/1.2	Section 1 Prescribing functions											
07/25/1.2.1	TLS IMOC July 2025 Please Note: TLS status finalised at IMOC all items are classified as non-Formulary unless stated otherwise. The committee received the TLS list that was agreed at the July 2025 IMOC meeting. The following have been agreed as Grey: <table><tr><th>Drug/Product</th><th>rationale</th></tr><tr><td>Efgartigimod</td><td>2</td></tr><tr><td>Erdosteine</td><td>3</td></tr><tr><td>Sumatriptan + naproxen sodium (new combination formulation)</td><td>4,7</td></tr><tr><td>Ruxolitinib (new topical formulation with new indication)</td><td>6</td></tr></table> The following have been agreed as Red:	Drug/Product	rationale	Efgartigimod	2	Erdosteine	3	Sumatriptan + naproxen sodium (new combination formulation)	4,7	Ruxolitinib (new topical formulation with new indication)	6	
Drug/Product	rationale											
Efgartigimod	2											
Erdosteine	3											
Sumatriptan + naproxen sodium (new combination formulation)	4,7											
Ruxolitinib (new topical formulation with new indication)	6											



	Bevacizumab gamma (new ophthalmic formulation)	1				
	Epoprostenol	1,6				
	Etanercept	1,6				
	Etoposide	1				
	Etelcalcetide	1				
	Etravirine	1,6				
	European Viper Venom Antiserum	1				
	Everolimus	1,6				
	Evolocumab	1,6				
	Factor VIIa, Factor VIII, Factor IX, Factor XIII	1,6				
	Faricimab	1				
	Fedratinib	1,6				
	Ferric carboxymaltose	1				
	Filgotinib	1				
	Filgrastim	1				
	Fingolimod	1,6				
	Fluocinolone acetonide intravitreal implant	1				
	Follitropin alfa, beta, delta & Follitropin alfa/lutropin alfa	1				
	Fomepizole	1				
	Fondaparinux	1				
	Fosamprenavir	1,6				
	Nivolumab plus ipilimumab	1,6				
	Somapacitan	1				
	Linzagolix	1				
	Spesolimab	1,3,6				
	Atezolizumab	1,6				
	Doxorubicin	1,6				
	Encorafenib	1,6				
	Enfuvirtide	1,6				
	Entecavir	1,6				
	Entrectinib	1,6				
	The following have been agreed as Green:					
	Sildenafil citrate (new orodispersible tablet formulation)				Use in adult men with erectile dysfunction	
	Action:					
	Karen Jennison to update the MPD					
07/25/1.2.2	NICE Guidance The NICE guidance report was received that was discussed at the July 2025 IMOC meeting. Ewa Gabzdyl informed the group of July’s NICE guidance. There were no actions for this group.					
07/25/1.2.3	MHRA - Drug Safety Update & NHS England Patient Safety alerts					



	The Safety report that was discussed at the July 2025 IMOC meeting was received. Ewa Gabzdyl informed the group of the items included in the safety report. MHRA- GLP-1 medicines for weight loss and diabetes: what you need to know Action: - The committee discussed that there are a lot of interactions to GLP-1 medicines not only for weight loss but also for diabetic patients, and where best to publish this information. It was agreed that the link GLP-1 medicines for weight loss and diabetes: what you need to know - GOV.UK should be added to the MPD, included in the next target meeting , Optimise RX and in the monthly bulletin. Rachel Hubbard will prepare some wording to for the bulletin. Senokot (sennoside or senna fruit extract, senna pods) products Action: - The committee agreed that there should be Optimise Rx messages to prompt prescribers that use in pregnancy and lactation is now contraindicated.	KJ &RH JC
07/25/1.2.4	IMOC Update Ashley Hill updated the group on the progress of the following documents that will be put on website / MPD when finalised. ➤ Tirzepatide type 2 diabetes guidance - Update on current guidance ➤ Tirzepatide for weight management FAQ for primary care Clinicians-already on MPD ➤ Lipid modification in younger adults with T2DM – To be added to MPD when get uploaded ➤ Acarizax and Grazax SCP - Update current SCP to be uploaded to IMOC website /MPD ➤ SMR/ Polypharmacy documents to be uploaded to IMOC website /MPD	
07/25/1.3	Matters Arising	
04/25/1.4.1	Valproate Review process The SY ICB Valproate Guidance in Primary Care document is available on the IMOC website, but the group decided that more discussion could be had around the use of these documents to support prescribers in Doncaster. Mallicka Chakrabarty discussed anti-epileptic and migraine medication which could influence foetal animalities and the direction from the faculty of sexual health on which contraception should be used particularly with Topiramate. Topiramate has enzyme-inducing activity and the recommended contraceptive options are Cu-IUD, LNG-IUD or DMPA plus condoms. This should be highlighted as patients take Topiramate for migraines and should be sighted on the implications if contraception is not used particularly on young patients. Mallicka shared a link : Message from	



	the CEU: Medication safety updates on Topiramate and DMPA FSRH which was agreed by the committee that the link should be hosted on the MPD under Topiramate. Action: Karen Jennison to update the MPD with the following under Topiramate.: Message from the CEU: Medication safety updates on Topiramate and DMPA FSRH	KJ
06/25/1.5.3	Thyroid register Rob Wise gave an update that Bassetlaw GPs were supportive of the guidance clinically, but it did bring up question regarding the closure of the thyroid register, and the impact it will have on primary care. They have discussed their concerns with Dr Muniyappa who is organising a separate meeting with Bassetlaw GPs. The chair explained that the thyroid register is not closing as there are a lot of complex patients, only simple hypothyroid patients are being discharged into Primary Care at this time, and there will be patients who require follow up and a shared care approach and these patients will stay under secondary care. The chair was happy to attend the meeting with Bassetlaw GPs and Dr Muniyappa if available, to give support and facilitate the conversation. There are contractual and commissioning issues still to be confirmed before the process can be rolled out, and the committee will be updated in due course.	
07/25/1.4	New Business	
07/25/1.4.1	Nocturnal enuresis/bed wetting in children The guidance document has been included in the MO bulletin, and desmopressin melt for bed wetting is already on the MPD traffic lighted as green. For completeness the guidance document has come to PMOC for information. The committee were happy to agree the traffic light status and guidance.	
07/25/1.4.2	Signature of proforma for SCP / Internal governance. Sonia Griffiths asked the committee for clarification whether it must be a GP who signs the shared care proformas. With the developing primary care workforce other clinicians such as Practice pharmacists who feel competent to do so could sign the proformas. Ewa Gabzdyl informed the group that this has been discussed at the recent IMOC subgroup. It was confirmed that currently the proformas do state that a GP signature is required, but as the process is going through some change this will be reviewed. The subgroup discussed that it is dependent on the individual practice internal processes whether other clinicians can sign on behalf of the GP. Ashley Hill informed the group that there is a task and finish group who are developing a process for the use of electronic proforma templates. This has been agreed at IMOC and is currently at being piloted at an	



	outpatient department at DRI, with a view to being rolled out throughout SY. Further information will be brought back to PMOC at future meetings.	
07/25/1.4.3	Changes in website arrangements Ashley Hill gave the committee an update that the Doncaster MO website will not be updated with new documents or any additions from today, and at some point, will be decommissioned by RDaSH and will disappear altogether. The MPD will continue to be updated as normal. Because some of the documents are housed on the website and linked to the MPD once the website is removed from service the links will go down on the MPD, and links will be updated with the new website when this goes live. The website action group is in the process of developing the SY ICB MO website, looking at formatting, re-naming documents and archiving old documents. It is hoped that the new SY ICB MO website will be going live on the 1st of September 2025.	
07/25/1.5	Any Other Business	
07/25/1.5.1	Pre-emptive prescribing Guidance review Lee Wilson has been working with colleagues to update the current pre-emptive prescribing guidelines. The group reviewed the draft version which was circulated for comment. The document will also be taken to RDaSH FT medicines management committee and DRI drug and therapeutic committee. It was noted that the palliative care formulary link does not work, and logos were on some of the pages but missed off the title page. It was suggested that the referral forms could be digital, and the question was raised whether the documents could be embedded in the Ardens template folder on the clinical systems. Steve Davies informed the group that he is currently looking into electronic prescribing. The committee agreed that any further comments could be sent to Lee Wilson before the next PMOC meeting and will liaise with Karen Jennison regarding logos and will update the link to the palliative care formulary. Action : • Lee Wilson to update link to palliative care formulary • Karen Jennison to put logos on the final document • Committee members to send any further comments to Lee Wilson • Final documents to return to Augusts PMOC for approval	LW KJ ALL KJ/LW
7/25/1.6	Minutes from other groups	
	SY ICB IMOC The minutes from the meeting held in June 2025 were received for information.	
	DBTHFT Drug & Therapeutics Committee (Monthly)	



	No Minutes available for this meeting			
	RDASH FT Medicines Management Committee (Monthly) The minutes from the meeting held in May 2025 were received for information.			
	Barnsley Place APC The minutes from the meeting held in May 2025 were received for information.			
	Rotherham Place MMC No Minutes available for this meeting			
	Sheffield Place APG The minutes from the meeting held in May 2025 were received for information.			
	Nottinghamshire No minutes available for this meeting			
	Close Section 1 and Open Section 2			
07/25/2.2	Section 2 Formulary functions			
07/25/2.2.1	New Product request - N/A			
07/25/2.2.2	Formulary and MPD (Medicines and Products Directory) review July 2025 The formulary products were agreed as below:			
	Formulary Section	Item	Indication	PMOC Action
	4.7.3	lidocaine 5% medicated plaster	Post-Herpetic Neuralgia	Green . Prescribe generic brand Ralvo in primary care 1 st line green remove Versatis
	7.4.5	Sildenafil citrate (new orodispersible tablet formulation)	Use in adult men with erectile dysfunction	Green non formulary
	4.10.2	Varenicline & Bupropion	Smoking cessation	Not routinely to be prescribed by GPS but by the smoking cessation who prescribe but if there are exceptional circumstances GPs can prescribe. Green traffic light status.
	4.8.1- Levetiracetam injection The committee discussed this item in detail, on the MPD Levetiracetam injection is red hospital only drug. Currently there is a palliative care patient registered at a Worksop Practice who requires a prescription for Levetiracetam for a syringe driver. The practice will not prescribe as it is traffic lighted Red, the hospital consultant switched the patient from oral Levetiracetam to IV as it was better suited for the patient, the patient was discharged with a supply. The patient’s supply has now run out. Lee Wilson asked the committee whether the traffic light status of Levetiracetam injection could be switched to Amber as previously on the old formulary, but as the DRI formulary has now been transferred to the MPD the traffic			



	light status could have been changed by mistake. It was noted that the injectable dose is the same as the oral dose and that it is off label using it as subcutaneous injection . The committee also discussed that it is the decision of the prescriber whether they are happy to prescribe Levetiracetam injection as the MPD is used as a guide. There was some nervousness from changing traffic light status as it is not a familiar formulation to primary care prescribers and an information guide would be useful. The committee discussed due to the current process that a change in traffic light status should mean that an IMOC application form should be completed and discussed at IMOC to make the final decision. Action: • Karen Jennison to make the agreed amendments to the MPD • Lee Wilson to complete IMOC application form including prescribing information and send to Ashley Hill <i>Post meeting note : Ralvo is now discontinued and should not be added to the MPD</i>	KJ LW
07/25/2.3	Matters Arising	
07/25/2.4	New Business	
07/25/2.5	Any Other Business	
	Date and Time of Next Meeting The next PMOC meeting will be held on Thursday 21st August 2025 at 12:00 Via MS Teams	

